Methylmalonic Acid Links Vitamin B12 Deficiency to Bone Aging via Mitochondria

A new review establishes a mechanistic link between vitamin B12 metabolism and skeletal aging by focusing on methylmalonic acid (MMA), a metabolite that accumulates when B12 is deficient. The paper argues that elevated MMA directly impairs mitochondrial function in bone cells, contributing to osteoporosis and age-related bone loss. This is significant because while B12 deficiency is common in older adults (affecting 10-30% of those over 60), the mechanisms connecting it to bone health have been unclear. MMA accumulation disrupts mitochondrial metabolism in osteoblasts and osteoclasts, potentially explaining why B12 deficiency accelerates skeletal aging beyond its known neurological effects. The practical implications are substantial: MMA is easily measurable in blood and urine, making it a potential biomarker for bone health risk in older adults. More importantly, B12 supplementation is safe, inexpensive, and widely available. If the MMA-mitochondria-bone connection holds up in intervention trials, optimizing B12 status could become a straightforward strategy for preserving bone health with aging. The review suggests we should be monitoring MMA levels, not just B12, in older adults at risk for osteoporosis.